Literature DB >> 20376271

Analysis of Classes Used in the Treatment of Depression by Physician-reported Severity.

Susan Lenderts1, Amir H Kalali, Richard Weisler.   

Abstract

We analyzed use of therapeutic drug classes for the treatment of depression by the three levels of physician-reported disease severity (mild, moderate, and severe) to understand if the mix of therapeutic classes used to treat depression changes as disease severity increases. Prior to analyzing drug uses in each severity category, we established that in the 12 months ending November 2009, the majority of patients (65%) were assigned a severity rating of 'moderate' by their physician; 27 percent and eight percent of patients were designated as 'mild' and 'severe,' respectively. In general, we found that as disease severity changes, so too do the proportions of the various therapeutic classes used in depression. The differences in class mix by severity have persisted at least since the 12 months ending December 2008, and it appears that the mix of drug classes used in severe depression are becoming less similar to the class mix for moderate depression over time.

Entities:  

Keywords:  depression; depression treatment; mild depression; moderate depression; physician-reported severity; severe depression; severity

Year:  2010        PMID: 20376271      PMCID: PMC2848467     

Source DB:  PubMed          Journal:  Psychiatry (Edgmont)        ISSN: 1550-5952


  19 in total

Review 1.  Long-term lithium treatment in the prevention of suicidal behavior in bipolar disorder patients.

Authors:  Leonardo Tondo; Ross J Baldessarini
Journal:  Epidemiol Psichiatr Soc       Date:  2009 Jul-Sep

2.  Treatment of depression: an update on antidepressant monotherapy and combination therapy.

Authors:  Susan Lenderts; Amir Kalali
Journal:  Psychiatry (Edgmont)       Date:  2009-08

3.  A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II).

Authors:  Susan L McElroy; Richard H Weisler; William Chang; Bengt Olausson; Björn Paulsson; Martin Brecher; Vasavan Agambaram; Charles Merideth; Arvid Nordenhem; Allan H Young
Journal:  J Clin Psychiatry       Date:  2010-01-26       Impact factor: 4.384

4.  Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report.

Authors:  A John Rush; Madhukar H Trivedi; Stephen R Wisniewski; Andrew A Nierenberg; Jonathan W Stewart; Diane Warden; George Niederehe; Michael E Thase; Philip W Lavori; Barry D Lebowitz; Patrick J McGrath; Jerrold F Rosenbaum; Harold A Sackeim; David J Kupfer; James Luther; Maurizio Fava
Journal:  Am J Psychiatry       Date:  2006-11       Impact factor: 18.112

5.  What did STAR*D teach us? Results from a large-scale, practical, clinical trial for patients with depression.

Authors:  Bradley N Gaynes; Diane Warden; Madhukar H Trivedi; Stephen R Wisniewski; Maurizio Fava; A John Rush
Journal:  Psychiatr Serv       Date:  2009-11       Impact factor: 3.084

6.  Extended release quetiapine fumarate monotherapy in major depressive disorder: a placebo- and duloxetine-controlled study.

Authors:  Andrew J Cutler; Stuart A Montgomery; David Feifel; Arthur Lazarus; Mikael Aström; Martin Brecher
Journal:  J Clin Psychiatry       Date:  2009-04-07       Impact factor: 4.384

7.  Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study.

Authors:  Michael Bauer; Herman W Pretorius; Eric L Constant; Willie R Earley; Johan Szamosi; Martin Brecher
Journal:  J Clin Psychiatry       Date:  2009-04-07       Impact factor: 4.384

8.  Chronic forms of major depression are still undertreated in the 21st century: systematic assessment of 801 patients presenting for treatment.

Authors:  James H Kocsis; Alan J Gelenberg; Barbara Rothbaum; Daniel N Klein; Madhukar H Trivedi; Rachel Manber; Martin B Keller; Robert Howland; Michael E Thase
Journal:  J Affect Disord       Date:  2008-02-12       Impact factor: 4.839

9.  Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report.

Authors:  Maurizio Fava; A John Rush; Jonathan E Alpert; G K Balasubramani; Stephen R Wisniewski; Cheryl N Carmin; Melanie M Biggs; Sidney Zisook; Andrew Leuchter; Robert Howland; Diane Warden; Madhukar H Trivedi
Journal:  Am J Psychiatry       Date:  2008-01-02       Impact factor: 18.112

10.  Residual symptoms after remission of major depressive disorder with citalopram and risk of relapse: a STAR*D report.

Authors:  A A Nierenberg; M M Husain; M H Trivedi; M Fava; D Warden; S R Wisniewski; S Miyahara; A J Rush
Journal:  Psychol Med       Date:  2009-05-22       Impact factor: 7.723

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.